We previously showed that the innovative radical scavenger bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)-decandioate (IAC) improves metabolic dysfunctions in a diabetic mouse model. Here, we compared the in vivoeffects of IAC with those of the anti-diabetic drugs pioglitazone (PIO) and exendin-4 (EX-4). Diabetes wasinduced in C57Bl/6J mice by streptozotocin and nicotinamide administration. Paralleled by healthy controls,diabetic animals (D) were randomly assigned to fourgroups and treated daily for 7 consecutive weeks:Dþsaline,ip;DþIAC 30 mg/kg b.w.,ip;DþPIO 10 mg/kg b.w.per os;andDþEX-4, 50μg/kg b.w.,ip.Ourresults show that IAC reduced basal hyperglycemia and improved glucose tolerance better than PIO or EX-4.Interestingly, in the heart of diabetic mice, IAC treatment normalized the increased levels of GSSG/GSH ratioand thiobarbituric acid reactive substances, indexes of oxidative stress and damage, while PIO and EX-4 wereless effective. As supported by immunohistochemical data, IAC markedly prevented diabetic isletβ-cell reduceddensity, differently from PIO and EX-4 that had only a moderate effect. Interestingly, in diabetic animals, IACtreatment enhanced the activity of pancreatic-duodenal homeobox 1 (PDX-1), an oxidative stress-sensitivetranscription factor essential for maintenance ofβ-cell function, as evaluated by quantification of its nuclearimmunostaining, whereas PIO or EX-4 treatments did not. Altogether, these observations support theimprovement of the general redox balance andβ-cell function induced by IAC treatment in streptozotocin-nicotinamide diabetic mice. Furthermore, in this model, the correction of diabetic alterations was betterobtained by treatment with the radical scavenger IAC than with pioglitazone or exendin-4.

Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice.

NOVELLI, MICHELA;FUNEL, NICCOLA;MASINI, MATILDE;DE TATA, VINCENZO;CAMPANI, DANIELA;MASIELLO, PELLEGRINO
2014

Abstract

We previously showed that the innovative radical scavenger bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl)-decandioate (IAC) improves metabolic dysfunctions in a diabetic mouse model. Here, we compared the in vivoeffects of IAC with those of the anti-diabetic drugs pioglitazone (PIO) and exendin-4 (EX-4). Diabetes wasinduced in C57Bl/6J mice by streptozotocin and nicotinamide administration. Paralleled by healthy controls,diabetic animals (D) were randomly assigned to fourgroups and treated daily for 7 consecutive weeks:Dþsaline,ip;DþIAC 30 mg/kg b.w.,ip;DþPIO 10 mg/kg b.w.per os;andDþEX-4, 50μg/kg b.w.,ip.Ourresults show that IAC reduced basal hyperglycemia and improved glucose tolerance better than PIO or EX-4.Interestingly, in the heart of diabetic mice, IAC treatment normalized the increased levels of GSSG/GSH ratioand thiobarbituric acid reactive substances, indexes of oxidative stress and damage, while PIO and EX-4 wereless effective. As supported by immunohistochemical data, IAC markedly prevented diabetic isletβ-cell reduceddensity, differently from PIO and EX-4 that had only a moderate effect. Interestingly, in diabetic animals, IACtreatment enhanced the activity of pancreatic-duodenal homeobox 1 (PDX-1), an oxidative stress-sensitivetranscription factor essential for maintenance ofβ-cell function, as evaluated by quantification of its nuclearimmunostaining, whereas PIO or EX-4 treatments did not. Altogether, these observations support theimprovement of the general redox balance andβ-cell function induced by IAC treatment in streptozotocin-nicotinamide diabetic mice. Furthermore, in this model, the correction of diabetic alterations was betterobtained by treatment with the radical scavenger IAC than with pioglitazone or exendin-4.
Novelli, Michela; Canistro, D; Martano, M; Funel, Niccola; Sapone, A; Melega, S; Masini, Matilde; DE TATA, Vincenzo; Pippa, A; Vecoli, V; Campani, Daniela; De Siena, R; Soleti, A; Paolini, M; Masiello, Pellegrino
File in questo prodotto:
File Dimensione Formato  
Novelli 2014.pdf

solo utenti autorizzati

Tipologia: Versione finale editoriale
Licenza: Importato da Ugov Ricerca - Accesso privato/ristretto
Dimensione 1.69 MB
Formato Adobe PDF
1.69 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/438669
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact